Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals.

Pathogens & immunity

Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H.
PMID: 28936485
Pathog Immun. 2017;2(3):310-334. doi: 10.20411/pai.v2i3.207. Epub 2017 Aug 02.

BACKGROUND: In HIV infection, lymphoid tissue is disrupted by fibrosis. Angiotensin converting enzyme inhibitors have anti-fibrotic properties. We completed a pilot study to assess whether the addition of lisinopril to antiretroviral therapy (ART) reverses fibrosis of gut tissue, and...

Cite
Cockerham LR, Yukl SA, Harvill K, et al. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathog Immun. 2017;2(3):310-334doi: 10.20411/pai.v2i3.207.
Cockerham, L. R., Yukl, S. A., Harvill, K., Somsouk, M., Joshi, S. K., Sinclair, E., Liegler, T., Hoh, R., Lyons, S., Hunt, P. W., Rupert, A., Sereti, I., Morcock, D. R., Rhodes, A., Emson, C., Hellerstein, M. K., Estes, J. D., Lewin, S., Deeks, S. G., & Hatano, H. (2017). A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathogens & immunity, 2(3), 310-334. https://doi.org/10.20411/pai.v2i3.207
Cockerham, Leslie R, et al. "A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals." Pathogens & immunity vol. 2,3 (2017): 310-334. doi: https://doi.org/10.20411/pai.v2i3.207
Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathog Immun. 2017;2(3):310-334. doi: 10.20411/pai.v2i3.207. Epub 2017 Aug 02. PMID: 28936485; PMCID: PMC5604865.
Copy Download .nbib Format: NLM
Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation.

Journal of the American Heart Association

Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, Maka K, Martin JN, Ganz P, Deeks SG.
PMID: 23130122
J Am Heart Assoc. 2012 Apr;1(2). doi: 10.1161/JAHA.111.000422. Epub 2012 Apr 24.

BACKGROUND: Shear stress gradients and inflammation have been causally associated with atherosclerosis development in carotid bifurcation regions. The mechanism underlying higher levels of carotid intima-media thickness observed among HIV-infected individuals remains unknown.METHODS AND RESULTS: We measured carotid intima-media thickness...

Cite
Hsue PY, Scherzer R, Hunt PW, et al. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc. 2012;1(2)doi: 10.1161/JAHA.111.000422.
Hsue, P. Y., Scherzer, R., Hunt, P. W., Schnell, A., Bolger, A. F., Kalapus, S. C., Maka, K., Martin, J. N., Ganz, P., & Deeks, S. G. (2012). Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. Journal of the American Heart Association, 1(2), . https://doi.org/10.1161/JAHA.111.000422
Hsue, Priscilla Y, et al. "Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation." Journal of the American Heart Association vol. 1,2 (2012). doi: https://doi.org/10.1161/JAHA.111.000422
Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, Maka K, Martin JN, Ganz P, Deeks SG. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc. 2012 Apr;1(2). doi: 10.1161/JAHA.111.000422. Epub 2012 Apr 24. PMID: 23130122; PMCID: PMC3487373.
Copy Download .nbib Format: NLM
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.

Open forum infectious diseases

Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ.
PMID: 27757411
Open Forum Infect Dis. 2016 Oct 07;3(4):ofw189. doi: 10.1093/ofid/ofw189. eCollection 2016 Oct.

In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These...

Cite
Delagrèverie HM, Delaugerre C, Lewin SR, et al. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis. 2016;3(4):ofw189doi: 10.1093/ofid/ofw189.
Delagrèverie, H. M., Delaugerre, C., Lewin, S. R., Deeks, S. G., & Li, J. Z. (2016). Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open forum infectious diseases, 3(4), ofw189. https://doi.org/10.1093/ofid/ofw189
Delagrèverie, Héloïse M, et al. "Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents." Open forum infectious diseases vol. 3,4 (2016): ofw189. doi: https://doi.org/10.1093/ofid/ofw189
Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis. 2016 Oct 07;3(4):ofw189. doi: 10.1093/ofid/ofw189. eCollection 2016 Oct. PMID: 27757411; PMCID: PMC5066458.
Copy Download .nbib Format: NLM
Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease.

AIDS research and therapy

Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM.
PMID: 25180041
AIDS Res Ther. 2014 Aug 05;11:27. doi: 10.1186/1742-6405-11-27. eCollection 2014.

The level (or frequency) of circulating monocyte subpopulations such as classical (CD14(hi)CD16(-)) and non-classical (CD14(dim)CD16(+)) monocytes varies during the course of HIV disease progression and antiretroviral therapy (ART). We hypothesized that such variation and/or differences in the degree to...

Cite
Seu L, Ortiz GM, Burt TD, et al. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014;11:27doi: 10.1186/1742-6405-11-27.
Seu, L., Ortiz, G. M., Burt, T. D., Deeks, S. G., Martin, J. N., & McCune, J. M. (2014). Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS research and therapy, 1127. https://doi.org/10.1186/1742-6405-11-27
Seu, Lillian, et al. "Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease." AIDS research and therapy vol. 11 (2014): 27. doi: https://doi.org/10.1186/1742-6405-11-27
Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014 Aug 05;11:27. doi: 10.1186/1742-6405-11-27. eCollection 2014. PMID: 25180041; PMCID: PMC4150425.
Copy Download .nbib Format: NLM
Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response.

The Journal of infectious diseases

Wu G, Zuck P, Goh SL, Milush JM, Vohra P, Wong JK, Somsouk M, Yukl SA, Shacklett BL, Chomont N, Haase AT, Hatano H, Schacker TW, Deeks SG, Hazuda DJ, Hunt PW, Howell BJ.
PMID: 33693750
J Infect Dis. 2021 Nov 16;224(9):1593-1598. doi: 10.1093/infdis/jiab121.

We demonstrate that human immunodeficiency virus (HIV) gag p24 protein is more readily detected in gut and lymph node tissues than in blood CD4+ T cells and correlates better with CD4 count during antiretroviral therapy (ART). Gut p24 levels...

Cite
Wu G, Zuck P, Goh SL, et al. Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. J Infect Dis. 2021;224(9):1593-1598doi: 10.1093/infdis/jiab121.
Wu, G., Zuck, P., Goh, S. L., Milush, J. M., Vohra, P., Wong, J. K., Somsouk, M., Yukl, S. A., Shacklett, B. L., Chomont, N., Haase, A. T., Hatano, H., Schacker, T. W., Deeks, S. G., Hazuda, D. J., Hunt, P. W., & Howell, B. J. (2021). Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. The Journal of infectious diseases, 224(9), 1593-1598. https://doi.org/10.1093/infdis/jiab121
Wu, Guoxin, et al. "Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response." The Journal of infectious diseases vol. 224,9 (2021): 1593-1598. doi: https://doi.org/10.1093/infdis/jiab121
Wu G, Zuck P, Goh SL, Milush JM, Vohra P, Wong JK, Somsouk M, Yukl SA, Shacklett BL, Chomont N, Haase AT, Hatano H, Schacker TW, Deeks SG, Hazuda DJ, Hunt PW, Howell BJ. Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. J Infect Dis. 2021 Nov 16;224(9):1593-1598. doi: 10.1093/infdis/jiab121. PMID: 33693750; PMCID: PMC8599810.
Copy Download .nbib Format: NLM
p16INK4a Expression and Immunologic Aging in Chronic HIV Infection.

PloS one

Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D.
PMID: 27861555
PLoS One. 2016 Nov 18;11(11):e0166759. doi: 10.1371/journal.pone.0166759. eCollection 2016.

Chronic HIV infection is characterized by increased immune activation and immunosenescence. p16 INK4a (p16) is a member of the cyclin-dependent kinase antagonist family that inhibits cellular proliferation, and its protein expression increases during normal chronological aging. However, some infectious...

Cite
Ribeiro SP, Milush JM, Cunha-Neto E, et al. p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2016;11(11):e0166759doi: 10.1371/journal.pone.0166759.
Ribeiro, S. P., Milush, J. M., Cunha-Neto, E., Kallas, E. G., Kalil, J., Passero, L. F. D., Hunt, P. W., Deeks, S. G., Nixon, D. F., & SenGupta, D. (2016). p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PloS one, 11(11), e0166759. https://doi.org/10.1371/journal.pone.0166759
Ribeiro, Susan Pereira, et al. "p16INK4a Expression and Immunologic Aging in Chronic HIV Infection." PloS one vol. 11,11 (2016): e0166759. doi: https://doi.org/10.1371/journal.pone.0166759
Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2016 Nov 18;11(11):e0166759. doi: 10.1371/journal.pone.0166759. eCollection 2016. PMID: 27861555; PMCID: PMC5115792.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries